VYGR
Voyager Therapeutics, Inc.Company with tickers: VYGR
CIK
1640266
CUSIP
92915B106
Shares Outstanding
60,421,287
13F Activity (30d)
34 filings
31 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $2,593,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $32,863,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $24,602,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-30,270,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-27,937,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.47 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.47 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Single Reportable Segment | $40,907,000 | $250,008,000 | $80,001,000 | $40,374,000 |